Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date

Vladimir Lerner, Peter J.A. McCaffery, Michael S. Ritsner

    Research output: Contribution to journalArticlepeer-review

    9 Scopus citations


    This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.

    Original languageEnglish
    Pages (from-to)269-280
    Number of pages12
    JournalCNS Drugs
    Issue number4
    StatePublished - 1 Apr 2016

    ASJC Scopus subject areas

    • Clinical Neurology
    • Psychiatry and Mental health
    • Pharmacology (medical)


    Dive into the research topics of 'Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date'. Together they form a unique fingerprint.

    Cite this